Merus Petosemtamab in Combination with Pembrolizumab Interim Data
Merus Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L rm HNSCC Merus NV Tue May 28 2024 700 AM 7 min read
Merus Announces Publication of an Abstract on Petosemtamab as 2L
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L HNSCC Conference call on Saturday Dec 7 at 900 am ET to discuss
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L rm HNSCC Merus NV Fri Dec 6 2024 1030 PM 10 min read
Petosemtamab MCLA158 with pembrolizumab as firstline 1L treatment
Merus Announces Publication of an Abstract on Petosemtamab GlobeNewswire
Petosemtamab clinical data in rm HNSCC continues to demonstrate potentially practice changing efficacy and safety both as monotherapy in 2L and in combination with pembrolizumab in 1L PDL1
Merus 39 Petosemtamab Monotherapy Interim Knowledge Continues
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate
All statements contained in this press release that do not relate to matters of historical fact should be considered forwardlooking statements including without limitation statements regarding the clinical development of our clinical candidates including petosemtamab future clinical trial results or interim data clinical activity and
Merus Petosemtamab Monotherapy Interim Data Continues to GlobeNewswire
In the dose escalation part of a phase 12 study the recommended phase 2 dose RP2D was determined to be 1500 mg every 2 weeks Q2W Interim data of petosemtamab monotherapy at the RP2D in 2L3L HNSCC led to a 372 overall response rate ORR per investigator with 60 months mo median duration of response DOR Cohen Cancer Research 2023
Petosemtamab clinical data in rm HNSCC continues to demonstrate potentially practice changing efficacy and safety both as monotherapy in 2L and in combination with pembrolizumab in 1L PDL1 expressing HNSCC said Fabian Zohren MD PhD Chief Medical Officer of Merus Further the monotherapy durability of petosemtamab thus far
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate
Merus 39 Petosemtamab Monotherapy Interim Knowledge Continues
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate
Merus Petosemtamab in Combination with Pembrolizumab Interim Data
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L HNSCC Conference call on Saturday Dec 7 at 900 am ET to discuss
Petosemtamab clinical data in rm HNSCC continues to demonstrate potentially practice changing efficacy and safety both as monotherapy in 2L and in combination with pembrolizumab in 1L PDL1 expressing HNSCC said Fabian Zohren MD PhD Chief Medical Officer of Merus Further the monotherapy durability of petosemtamab thus far
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate
Petosemtamab clinical data in rm HNSCC continues to demonstrate potentially practice changing efficacy and safety both as monotherapy in 2L and in combination with pembrolizumab in 1L PDL1